Influence of L-citrulline supplementation along with conventional treatment and its effect on inflammatory markers in patients with non-alcoholic fatty liver disease
Abstract
This study evaluated the effect of L-citrulline supplementation combined with conventional therapy on inflammatory and hepatic markers in patients with non-alcoholic fatty liver disease (NAFLD). A total of 110 patients aged 35-45 years were enrolled in a 12-week quasi-experimental study and divided into two groups: G0 (conventional treatment only) and G1 (conventional treatment plus 2 g/day L-citrulline). Anthropometric measurements and biochemical parameters, including lipid profile, liver function tests, C-reactive protein (CRP), and tumor necrosis factor (TNF)-α, as well as dietary intake, were collected at baseline and post-intervention. The mean age was 42.03±4.89 years in G0 and 44.7±4.22 years in G1. Body mass index (BMI) and weight did not change significantly in either group. L-citrulline supplementation in G1 significantly reduced low-density lipoprotein and total cholesterol levels and improved high-density lipoprotein (p<0.05). TNF-α levels also decreased significantly in the treatment group (p=0.0032), whereas CRP and aspartate aminotransferase showed no significant changes. These findings indicate that L-citrulline supplementation, as an adjunct to conventional therapy, improves inflammatory and lipid parameters in NAFLD patients, particularly TNF-α, low-density lipoprotein, and total cholesterol, without affecting BMI, weight, or CRP. Future multicenter randomized studies are recommended to confirm these results.
References
- Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract 2020;35:72-84.
- Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci 2021;22:2350.
- Palladini G, Di Pasqua LG, Berardo C, et al. Animal models of steatosis (NAFLD) and steatohepatitis (NASH) exhibit hepatic lobe-specific gelatinases activity and oxidative stress. Can J Gastroenterol Hepatol 2019;3:201-9.
- Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-65.
- Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction- associated fatty liver disease (MAFLD)—new terminology in pediatric patients as a step in good scientific direction? J Clin Med 2021;10:924-36.
- Farrell GC, Wong VWS, Chitturi S. NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013;10:307-18.
- Bahri S, Zerrouk N, Aussel C, et al. Citrulline: from metabolism to therapeutic use. Nutrition 2013;29:479-84.
- Curis E, Crenn P, Cynober L. Citrulline and the gut. Curr Opin Clin Nutr Metab Care 2007;10:620-6.
- Khalaf D, Krüger M, Wehland M, et al. The effects of oral l-arginine and l-citrulline supplementation on blood pressure. Nutrients 2019;11:1679.
- Azizi S, Mahdavi R, Mobasseri M, et al. The impact of L‐citrulline supplementation on glucose homeostasis, lipid profile, and some inflammatory factors in overweight and obese patients with type 2 diabetes: A double‐blind randomized placebo‐controlled trial. Phytother Res 2021;35:3157-66.
- Chien SJ, Lin KM, Kuo HC, et al. Two different approaches to restore renal nitric oxide and prevent hypertension in young spontaneously hypertensive rats: l-citrulline and nitrate. Transl Res 2104;163:43-52.
- Rajcic D, Baumann A, Hernández-Arriaga A, et al. Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase. Redox Biol 2021;41:101879.
- Darabi Z, Darand M, Yari Z, Agah S. Effects of citrulline on non-alcoholic fatty liver disease: a randomized-controlled clinical trial. Iranian J Nutr Sci Food Technol 2019;14:1-9.
- Darabi Z, Darand M, Yari Z, et al. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: A randomized, double blind, placebo-controlled, clinical trial. BMC Res Notes 2019;12:89.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.